The stock price of Biomea Fusion Inc (NASDAQ: BMEA) has dropped by -4.64 compared to previous close of 1.94. Despite this, the company has seen a fall of -3.14% in its stock price over the last five trading days. globenewswire.com reported 2025-06-23 that SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of new preclinical and clinical data for icovamenib, the company’s investigational oral menin inhibitor, at the 85th Scientific Sessions of the American Diabetes Association (ADA) June 20–23, 2025 in Chicago.
Is It Worth Investing in Biomea Fusion Inc (NASDAQ: BMEA) Right Now?
Additionally, the 36-month beta value for BMEA is -0.18. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for BMEA is 49.78M and currently, short sellers hold a 24.03% ratio of that float. The average trading volume of BMEA on June 26, 2025 was 2.21M shares.
BMEA’s Market Performance
BMEA’s stock has seen a -3.14% decrease for the week, with a 30.28% rise in the past month and a -26.59% fall in the past quarter. The volatility ratio for the week is 11.94%, and the volatility levels for the past 30 days are at 16.39% for Biomea Fusion Inc. The simple moving average for the past 20 days is -15.93% for BMEA’s stock, with a -61.63% simple moving average for the past 200 days.
Analysts’ Opinion of BMEA
Many brokerage firms have already submitted their reports for BMEA stocks, with Piper Sandler repeating the rating for BMEA by listing it as a “Overweight.” The predicted price for BMEA in the upcoming period, according to Piper Sandler is $7 based on the research report published on June 03, 2025 of the current year 2025.
Edward Jones, on the other hand, stated in their research note that they expect to see BMEA reach a price target of $128. The rating they have provided for BMEA stocks is “Buy” according to the report published on October 09th, 2024.
Truist gave a rating of “Buy” to BMEA, setting the target price at $54 in the report published on September 27th of the previous year.
BMEA Trading at -4.46% from the 50-Day Moving Average
After a stumble in the market that brought BMEA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.85% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMEA starting from Hitchcock Michael J.M., who purchase 10,000 shares at the price of $10.06 back on Sep 30 ’24. After this action, Hitchcock Michael J.M. now owns 15,000 shares of Biomea Fusion Inc, valued at $100,600 using the latest closing price.
Stock Fundamentals for BMEA
Current profitability levels for the company are sitting at:
- -108.79 for the present operating margin
- 0.34 for the gross margin
The net margin for Biomea Fusion Inc stands at -81.45. The total capital return value is set at -3.77. Equity return is now at value -156.81, with -115.08 for asset returns.
Based on Biomea Fusion Inc (BMEA), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -14.32.
Currently, EBITDA for the company is -136.68 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 34.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
In conclusion, Biomea Fusion Inc (BMEA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
